Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer

• Published in: Scientific reports Vol. 13; no. 1; p. 18126
• Main Authors: Park, Hwa Kyung, Yoon, Chang-Seok, Na, Young-Ok, Lee, Jae-Kyeong, Oh, Hyung-Joo, Park, Ha-Young, Kho, Bo-Gun, Kim, Tae-Ok, Shin, Hong-Joon, Kwon, Yong-Soo, Oh, In-Jae, Kim, Yu-Il, Lim, Sung-Chul, Kim, Young-Chul, Park, Cheol-Kyu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/1807/1809; 692/308/53/2421; 692/308/53/2422; 692/308/53/2423; 692/4028/67/1612/1350; 692/4028/67/1612/2143; 692/499; Cancer therapies; Humanities and Social Sciences; Lung cancer; Lung diseases; multidisciplinary; Pneumonitis; Procalcitonin; Risk factors; Science; Science (multidisciplinary); Survival
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-45170-8

In this study, we aimed to investigate the feasibility of serum Krebs von den Lungen-6 (KL-6) as a potential biomarker for treatment-related ILD (TR-ILD) in lung cancer. We recruited patients with lung cancer in whom KL-6 was measured to differentiate between pneumonia and ILD (category 1), diagnose and assess the severity of suspicious ILD (category 2), or evaluate baseline levels before cancer treatment (category 3). Among 1,297 patients who underwent KL-6 testing, 422 had lung cancer, and TR-ILD was detected in 195 patients. In categories 1–2, median KL-6 level was higher in drug-induced ILD or acute exacerbation of underlying ILD than in no ILD or radiation-induced pneumonitis, and it was correlated with the severity of TR-ILD. High KL-6 level (cut-off: > 436U/mL) was an independent risk factor for severe TR-ILD, and low KL-6 level with high procalcitonin level (> 0.5 ng/mL) could exclude severe TR-ILD. Patients with severe TR-ILD had worse overall survival than those without, whereas high baseline KL-6 level was associated with worse survival, especially in patients without severe TR-ILD. Therefore, serum KL-6 may be a surrogate marker for predicting the occurrence and assessing the severity of TR-ILD at the time of suspected ILD and before lung cancer treatment.